This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Intuitive Surgical Hits 52-Week High on Multiple Positives
by Zacks Equity Research
Shares of leading provider of robotic-assisted surgery, Intuitive Surgical, Inc. (ISRG) rallied to a new 52-week high of $770.28 on Mar 28, closing a tad lower at $764.47.
3 Medical Device Stocks to Brave Policy Uncertainty
by Zacks Equity Research
We believe stocks with strong fundamentals that also have a significant share of their business overseas may well brace themselves in the on-going conundrum. They will make lucrative additions to your portfolio.
IDEXX (IDXX) Poised on Strong Fundamentals, Innovations
by Zacks Equity Research
On Mar 14, we issued an updated research report on IDEXX Laboratories, Inc. (IDXX).
ABIOMED Impella Heart Pump Reduces Kidney Injury during PCI
by Zacks Equity Research
A new study demonstrates that ABIOMED's flagship Impella 2.5 heart pump can reduce the risk of acute kidney injury during high-risk percutaneous coronary intervention (PCI).
Cooper Companies (COO) Receives ISO 15189 Accreditation
by Zacks Equity Research
The Cooper Companies Inc. (COO) announced that its London and Nottingham-based laboratories received the International Organization for Standardization 15189 accreditation.
C. R. Bard (BCR) Well Poised for Growth, Macro Woes Remain
by Zacks Equity Research
We issued an updated research report on C. R. Bard Inc. (BCR) on Mar 8, 2017.
Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Share price of Baxter International Inc. (BAX), a global medical technology company, rallied to a new 52-week high of $51.43 on Mar 8, eventually closing a bit lower at $51.36.
Intersect ENT: FDA Submission of RESOLVE Implant, Stock Up
by Zacks Equity Research
Intersect ENT, Inc (XENT) recently announced the submission of a New Drug Application (NDA) approval with the U.S. FDA for reviewing its investigational RESOLVE steroid releasing implant.
OPKO Health (OPK) Launches Prenatal Testing Tool ClariTest
by Zacks Equity Research
OPKO Health Inc. (OPK) recently announced the launch of a non-invasive medical test to detect fetal abnormalities.
Meridian (VIVO) to Provide LeadCare Testing System in Africa
by Zacks Equity Research
Meridian Bioscience, Inc. (VIVO), a renowned life sciences company, recently signed an exclusive distribution agreement with Biofirm Technologies.
TransEnterix (TRXC) Reports Wider-Than-Expected Loss in Q4
by Zacks Equity Research
TransEnterix, Inc. (TRXC) reported a loss of 12 cents per share in the fourth quarter of 2016, wider than the Zacks Consensus Estimate of a loss of 11 cents.
Masimo Announces Availability of RD SedLine Brain Sensors
by Zacks Equity Research
Masimo Corporation (MASI) recently announced the availability of the RD SedLine EEG sensor, which can be used with the company???s flagship SedLine Brain Function Monitoring technology.
Allscripts (MDRX) Acknowledged by LPP's CDIS Framework
by Zacks Equity Research
Allscripts Healthcare Solutions, Inc. (MDRX) recently announced that it has been accepted and acknowledged by the NHS London Procurement Partnership (LPP) in its Clinical and Digital Information Systems (CDIS) Framework.
IDEXX (IDXX) Up 5.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
IDEXX (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Ranked Momentum Stocks to Buy for February 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 14th:
Can the Rally in IDEXX Laboratories (IDXX) Shares Continue?
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) has been on the move lately as the stock has risen by 16.5% in the past four weeks, and it is currently trading well above its 20-Day SMA
Looking for a Growth Stock? Why It is Time to Focus on IDEXX Laboratories (IDXX)
by Zacks Equity Research
IDEXX Laboratories (IDXX) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
IDEXX Laboratories (IDXX) Q4 Earnings Rise; Tweaks View
by Zacks Equity Research
IDEXX Laboratories Inc. (IDXX) recorded fourth-quarter 2016 earnings per share (EPS) of 58 cents, up 21% year over year on a reported basis.
IDEXX Laboratories (IDXX) Beats Q4 Revenues, Y/Y EPS rises
by Zacks Equity Research
IDEXX Laboratories (IDXX) has seen growth in earnings year over year and has beaten the Zacks Consesnus Estimate in terms of revenue.
Medical Product Earnings Due on Feb 2: BDX, BSX, IDXX, ATHN
by Zacks Equity Research
The medical sector is likely to see 2.9% earnings growth on 5.7% higher revenues in the quarter.
IDEXX Laboratories (IDXX) Q4 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is slated to report fourth-quarter 2016 results on Feb 2, before the opening bell.
IDEXX Laboratories (IDXX) Set to Join the S&P 500 Index
by Zacks Equity Research
IDEXX Laboratories, Inc. (IDXX) is scheduled to join the coveted S&P 500 benchmark, after the market closes on Jan 4.
Neogen (NEOG) Acquires Brazilian Private Company Rogama
by Zacks Equity Research
Neogen Corporation (NEOG) announced that it has acquired Brazil-based Rogama Industria e Comercio Ltda.
Patterson and ADPI Extend Partnership for Dental Platform
by Zacks Equity Research
Patterson Companies Inc. (PDCO), a leading distributor and seller of dental and animal health products, announced that it has extended its partnership with American Dental Partners or ADPI.
Mazor Robotics Receives Order for Three Mazor X Systems
by Zacks Equity Research
Israel-based developer of robotic technology and products, Mazor Robotics Ltd. (MZOR), recently announced a three-system order for the Mazor X, from a leading mid-Atlantic health care organization.